Welcome to our dedicated page for PARKERVISION SEC filings (Ticker: PRKR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
ParkerVision, Inc.'s SEC filings document an OTCQB-traded Florida corporation focused on proprietary RF technologies, wireless applications, licensing, and patent enforcement. Its 8-K filings report operating results, legal and appellate developments involving patent claims, and material events that affect the company's capital structure and disclosure record.
The filing record also covers registered direct common stock offerings under a Form S-3 shelf registration statement, exchanges of convertible promissory notes for common stock, unregistered equity issuance disclosures, and executive compensation arrangements under the company's long-term incentive plan. These documents address governance approvals, share-based awards, financing terms, and risk references tied to patent proceedings and funding activity.
ParkerVision, Inc. files a Prospectus Supplement registering 5,871,584 shares of Common Stock for resale by selling stockholders. The supplement attaches a Form 8-K reporting that on April 22, 2026 the Compensation Committee extended the expiration dates of previously granted, fully vested nonqualified stock options held by CEO Jeffrey Parker (2,660,000 options) and CFO Cynthia French (870,550 options) from August 7, 2026 to August 7, 2029 with no change to exercise price ($0.171) or share counts. The company expects to record a one-time non-cash share-based compensation charge of approximately $360,000 related to the modification. The resale proceeds will not be received by the company.
ParkerVision, Inc. registers 16,809,295 shares of Common Stock for resale under a prospectus supplement dated April 27, 2026.
The supplement states the 16,809,295 shares consist of convertible-note conversions, prior private placements, shares issued for services and payables, and warrants, and that the company will not receive proceeds from selling stockholders. The company may receive up to $3,900,000 if Aspire and Tailwinds warrants are exercised for cash; any proceeds are expected to be used for general working capital and corporate purposes.
Separately, the company disclosed a Compensation Committee action dated April 22, 2026 extending the expiration dates of outstanding options for the CEO (2,660,000 options) and CFO (870,550 options) from August 7, 2026 to August 7, 2029, which will result in an expected one-time non-cash share-based compensation charge of approximately $360,000.
ParkerVision, Inc. registers 18,014,164 shares of Common Stock for resale by selling stockholders under a prospectus supplement dated April 27, 2026.
The registration covers shares issuable upon conversion of convertible promissory notes across two tranches, shares issued for consulting services, and up to 1,800,000 shares issuable on a warrant with a $0.10 exercise price. The company will not receive proceeds from resales; if the Park Consulting Warrant is exercised for cash, the company would receive up to $180,000 to use for general working capital. The supplement attaches a Form 8-K reporting the Board Compensation Committee's approval to extend option expirations for two executives from August 7, 2026 to August 7, 2029, which will generate an estimated one-time, non-cash share-based compensation charge of approximately $360,000.
ParkerVision, Inc. files a Prospectus Supplement and attaches a Form 8-K to update its resale registration covering 17,189,660 shares of Common Stock. The supplement reconfirms resale registrations tied to prior private placements, a PIPE agreement with Aspire Capital, and convertible notes from 2018. The company will not receive proceeds from selling holders; issuer proceeds may occur only if certain warrants or PIPE-related instruments are exercised. The Form 8-K also discloses a Compensation Committee action to extend the expiration dates of previously awarded nonqualified stock options for CEO Jeffrey Parker (2,660,000 options) and CFO Cynthia French (870,550 options) from August 7, 2026 to August 7, 2029, with an unchanged exercise price of $0.171 per share. The company expects to record a one-time non-cash share-based compensation charge of approximately $360,000 related to the modification.
ParkerVision, Inc. supplements its April 19, 2019 prospectus to register 12,800,000 shares of Common Stock for resale by selling stockholders, consisting of up to 7,800,000 shares issuable on conversion of convertible promissory notes and 5,000,000 shares issuable upon exercise of a five-year warrant. The company will not receive proceeds from the resale; if the warrant is exercised for cash, the company would receive up to $800,000 to be used, if received, to fund patent enforcement actions and for general corporate purposes. The supplement also attaches a Form 8-K disclosing that the Compensation Committee approved an extension of the expiration dates of certain fully vested nonqualified stock options for the CEO and CFO from August 7, 2026 to August 7, 2029, which the company expects will result in a one-time non-cash share-based compensation charge of approximately $360,000.
ParkerVision, Inc. disclosed that its Compensation Committee approved changes to outstanding nonqualified stock options held by CEO Jeffrey Parker and CFO Cynthia French. The company extended the options’ expiration date from August 7, 2026 to August 7, 2029 to maintain their long-term incentive value.
The modified awards cover 2,660,000 options for Mr. Parker and 870,550 options for Ms. French, all originally granted on August 7, 2019 with an exercise price of $0.171 per share. These options were fully vested as of the modification date.
ParkerVision expects to record a one-time, non-cash share-based compensation charge of approximately $360,000 related to this modification. Only the expiration dates were changed; the exercise price, number of shares, vesting status, and all other terms remained the same, and no additional securities were issued.
ParkerVision, Inc. is registering for resale 9,387,500 shares of Common Stock under a prospectus supplement dated March 23, 2026, consisting of shares issued, shares issuable upon conversion of convertible notes, and shares issuable upon exercise of options.
The supplement states the company will not receive proceeds from selling shareholders; if the 200,000 Options are exercised for cash, the company would receive up to $42,620. The supplement attaches the company’s Form 10-K for the fiscal year ended December 31, 2025.
As context, shares outstanding were 147,535,024 as of March 19, 2026. The filing is a resale registration by selling holders under the existing Prospectus (Prospectus dated May 11, 2023).
ParkerVision, Inc. registers 16,638,353 shares of common stock for resale pursuant to a Prospectus Supplement dated March 23, 2026.
The shares are issuable upon conversion of convertible promissory notes dated between May 10, 2022 and August 3, 2022 at a fixed conversion price of $0.13 per share and are being resold by selling shareholders (resale offering). The Prospectus Supplement attaches the company’s Form 10-K for the fiscal year ended December 31, 2025 and updates disclosures.
Context: the company reported 147,535,024 shares outstanding as of March 19, 2026, cash and cash equivalents of $4.4M as of December 31, 2025, and convertible notes principal of $3.1M as of that date.
ParkerVision, Inc. registers 1,578,946 shares of Common Stock for resale under a prospectus supplement dated March 23, 2026. The registration consists of 1,052,631 shares of Common Stock and 526,315 shares issuable upon exercise of outstanding warrants. The company will not receive proceeds from resales by the selling stockholder; if the warrants are exercised for cash, ParkerVision would receive up to $526,315, which it expects to use for general working capital, including payment of litigation expenses.
The supplement incorporates ParkerVision’s Annual Report on Form 10-K for the fiscal year ended December 31, 2025, and updates the prospectus’ disclosures regarding the company’s patent enforcement-focused business, contingent funding arrangements, convertible debt, and substantial doubt about its ability to continue as a going concern.
ParkerVision, Inc. is registering 13,342,953 shares of Common Stock for resale by selling stockholders under a prospectus supplement dated March 23, 2026.
The registered shares consist of 7,962,722 shares issued under earlier purchase agreements, 3,230,942 shares and 1,619,289 shares underlying warrants issued in March 2021, and 530,000 shares issued for services. The company will not receive proceeds from resale by the selling stockholders, but could receive up to $2,833,756 if the Warrants are exercised for cash; any such proceeds are expected to be used for general working capital, including payment of litigation expenses.
This prospectus supplement updates the Prospectus (dated April 26, 2021) with information from the Company’s Annual Report on Form 10-K filed March 23, 2026. Shares outstanding were 147,535,024 as of March 19, 2026.